COVID-19: Clinical aspects and therapeutics responses
COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. wh...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2020-08-01
|
| Series: | Saudi Pharmaceutical Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1319016420301481 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849307341532430336 |
|---|---|
| author | Suliman Khan Ashaq Ali Hongwei Shi Rabeea Siddique Shabana Ghulam Nabi Junjie Hu Tiejun Wang Men Dong Wajid Zaman Guang Han |
| author_facet | Suliman Khan Ashaq Ali Hongwei Shi Rabeea Siddique Shabana Ghulam Nabi Junjie Hu Tiejun Wang Men Dong Wajid Zaman Guang Han |
| author_sort | Suliman Khan |
| collection | DOAJ |
| description | COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5–7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs. |
| format | Article |
| id | doaj-art-28b0433da9f1444bb385ba5dc294da9f |
| institution | Kabale University |
| issn | 1319-0164 |
| language | English |
| publishDate | 2020-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Saudi Pharmaceutical Journal |
| spelling | doaj-art-28b0433da9f1444bb385ba5dc294da9f2025-08-20T03:54:47ZengSpringerSaudi Pharmaceutical Journal1319-01642020-08-012881004100810.1016/j.jsps.2020.06.022COVID-19: Clinical aspects and therapeutics responsesSuliman Khan0Ashaq Ali1Hongwei Shi2Rabeea Siddique3 Shabana4Ghulam Nabi5Junjie Hu6Tiejun Wang7Men Dong8Wajid Zaman9Guang Han10Department of Cerebrovascular Diseases, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China; Corresponding authors.Wuhan Institute of Virology, Chinese Academy of Sciences, Xiao Hong Shan No.44, Wuhan, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaKey State Laboratory of Virology, School of Life Sciences, Wuhan University, Wuhan, ChinaDepartment of Cerebrovascular Diseases, the Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Xiao Hong Shan No.44, Wuhan, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaKey Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University,Shijiazhuang 050024, ChinaDepartment of Gastrointestinal Surgery , Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaDepartment of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Xiao Hong Shan No.44, Wuhan, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaState Key Laboratory of Systematic and Evolutionary Botany, Institute of Botany, Chinese Academy of Sciences, Beijing 100093, ChinaDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Corresponding authors.COVID-19 has created havoc in the world by causing thousands of demises in a short period of time. Up till now, several attempts have been made for potential therapeutics against SARS-COV2. In this retrospective, single-center study, we extracted data from 122 COVID-19, RT-PCR confirmed patients. who were treated with a new treatment strategy of lianhuaqingwen with Arbidol Hydrochloride. The patients were either asymptomatic or had mild symptoms for COVID-19 disease. Of 122 patients 21 (17.21%) patients developed severe conditions of COVID-19, while total 111 (90.9%) experienced mild symptoms such as fever in 93 (76.22%) patients, cough in 23 (20.17%) and muscle pain were observed in total 8 (7%) patients. Furthermore our newly applied drugs combination (Lianhuaqingwen and Arbidol Hydrochloride) showed therapeutic effects in 5–7 days in patients with mild symptoms with 98% recovery rate. These results indicate that COVID-19 patients with mild symptoms can be treated with Lianhuaqingwen and Arbidol Hydrochloride. However, extensive clinical investigations are required to confirm the effectiveness of these drugs.http://www.sciencedirect.com/science/article/pii/S1319016420301481COVID-19TherapeuticsMild symptomsTCMRecoveries |
| spellingShingle | Suliman Khan Ashaq Ali Hongwei Shi Rabeea Siddique Shabana Ghulam Nabi Junjie Hu Tiejun Wang Men Dong Wajid Zaman Guang Han COVID-19: Clinical aspects and therapeutics responses Saudi Pharmaceutical Journal COVID-19 Therapeutics Mild symptoms TCM Recoveries |
| title | COVID-19: Clinical aspects and therapeutics responses |
| title_full | COVID-19: Clinical aspects and therapeutics responses |
| title_fullStr | COVID-19: Clinical aspects and therapeutics responses |
| title_full_unstemmed | COVID-19: Clinical aspects and therapeutics responses |
| title_short | COVID-19: Clinical aspects and therapeutics responses |
| title_sort | covid 19 clinical aspects and therapeutics responses |
| topic | COVID-19 Therapeutics Mild symptoms TCM Recoveries |
| url | http://www.sciencedirect.com/science/article/pii/S1319016420301481 |
| work_keys_str_mv | AT sulimankhan covid19clinicalaspectsandtherapeuticsresponses AT ashaqali covid19clinicalaspectsandtherapeuticsresponses AT hongweishi covid19clinicalaspectsandtherapeuticsresponses AT rabeeasiddique covid19clinicalaspectsandtherapeuticsresponses AT shabana covid19clinicalaspectsandtherapeuticsresponses AT ghulamnabi covid19clinicalaspectsandtherapeuticsresponses AT junjiehu covid19clinicalaspectsandtherapeuticsresponses AT tiejunwang covid19clinicalaspectsandtherapeuticsresponses AT mendong covid19clinicalaspectsandtherapeuticsresponses AT wajidzaman covid19clinicalaspectsandtherapeuticsresponses AT guanghan covid19clinicalaspectsandtherapeuticsresponses |